A novel transdermal patch incorporating meloxicam: In vitro and in vivo characterization

International Journal of Pharmaceutics

Volumn 385, Issue 1-2, 2010, Pages 12-19

  Ah, Young Chang ^a   Choi, Jin Kyu ^a   Choi, Yang Kyu ^a   Ki, Han Moi ^a   Bae, Joon Ho ^a  

^a AmorePacific Corporation   (South Korea)

Author keywords

Meloxicam; Patch; Sodium methoxide; Solubility; Transdermal delivery

Indexed keywords

ACRYLIC CEMENT; ADHESIVE AGENT; CETOMACROGOL; DIISOPROPANOLAMINE; MELOXICAM; METHOXIDE SODIUM; PENETRATION ENHANCING AGENT; PIROXICAM; POVIDONE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; CRYSTAL; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY; SKIN SURFACE; TRANSDERMAL PATCH;

ACRYLIC RESINS; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DISEASE MODELS, ANIMAL; DOSAGE FORMS; DRUG COMPOUNDING; DRUG STABILITY; EDEMA; EXCIPIENTS; FREUND'S ADJUVANT; MICE; MICE, HAIRLESS; MYCOBACTERIUM; OSTEOARTHRITIS; PERMEABILITY; PIROXICAM; POVIDONE; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SKIN ABSORPTION; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; THIAZINES; THIAZOLES; TISSUE ADHESIVES;

EID: 72149129755     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.10.013     Document Type: Article

References (41)

1. Bastien M., Milpied-Homsi B., Baudot S., Dutartre H., and Litoux P. Ketopofen-induced contact photosensitivity disorders; 5 cases. Ann. Dermatol. Venereol. 124 (1997) 523-526
2. Bavbek S., Dursun A.B., Dursun E., Eryilmaz A., and Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Allerg. Immunol. (Paris) (2003) 393-396
3. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.H., Guzman R.E., Juneau P.L., Schrier D.J., and Kilgore K.S. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 11 (2003) 821-830
4. Busch U., Schmid J., Heizel G., Schmaus H., Baierl J., Huber C., and Roth W. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab. Dispos. (1998) 576-584
5. Chang J.S., Huang Y.B., Hou S.S., Wang R.J., Wu C.W., and Tsai Y.H. Formulation optimization of meloxicam sodium gel using response surface methodology. Int. J. Pharm. 338 (2007) 48-54
6. Cheong H.A., and Choi H.K. Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm. Res. 19 (2002) 1375-1380
7. Cheong H.A., and Choi H.K. Effect of ethanolamine salts and enhancers on the percutaneous absorption of piroxicam from a pressure sensitive adhesive matrix. Eur. J. Pharm. Sci. 18 (2003) 149-153
8. Dasandi B., Shivaprakash, Saroj H., and Bhat K.M. LC determination and pharmacokinetics of meloxicam. J. Pharm. Biomed. Anal. 28 (2002) 999-1004
9. Degner F., Sigmund R., and Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Ther. 22 (2000) 400-410
10. Draize J.H., Woodard G., and Calvey H.O. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82 (1944) 377-390
11. Engelhardt G., Homma D., Schlegel K., Utzmann R., and Schnitzer C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res. 44 (1995) 423-433
12. Galer B.S., Rowbotham M., Perander J., Devers A., and Friedman E. Topical dichlofenac patch relieves minor sports injury pain: results of multicenter controlled clinical trial. J. Pain. Symptom Manag. 19 (2000) 287-294
13. Gambero A., Becker T.L., Zago A.S., de Oliveira A.F., and Pedrazzoli Jr. J. Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors. Inflammopharmacology 13 (2005) 441-454
14. Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br. J. Clin. Pract. 49 (1995) 33-35
15. Gupta S.K., Bansal P., Bhardwaj R.K., Jaiswai J., and Velpandian T. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with dichlofenac and piroxicam gel in animal models: pharmacokinetic parameters after topical application. Skin Pharmcol. Appl. Skin Physiol. 15 (2002) 105-111
16. Hatanaka T., Kamon T., Morigaki S., Katayama K., and Koizumi T. Ion pair skin transport of a zwitterionic drug, cephalexin. J. Control. Release 66 (2000) 63-71
17. Heyneman C.A., Lawless-liday C., and Wall G.C. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 60 (2000) 555-574
18. Jantharaprapap R., and Stagni G. Effects of penetration enhancers on in-vitro permeability of meloxicam gels. Int. J. Pharm. 343 (2007) 26-33
19. Kamal A.A.H.M., Iimura N., Nabekura T., and Kitagawa S. Enhanced skin permeation dichlofenac by ion-pair formation and further enhancement by microemulsion. Chem. Pharm. Bull. 55 (2007) 368-371
20. Ki H.M., and Choi H.K. The effect of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam. Arch. Pharm. Res. 30 (2007) 215-221
21. Kimura E., Bersani-Amado C.A., Sudo L.S., Santos R.J., and Oga S. Pharmacokinetic profile of piroxicam β-cyclodextrin in rat plasma and lymph. Gen. Pharmacol. 28 (1997) 695-698
22. Lipscomb G.R., Wallis N., Armstrong G., and Rees W.D.W. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br. J. Clin. Pharmacol. 46 (1998) 133-137
23. Luger P., Daneck K., Engel W., Trummlits G., and Wagner K. Structure and physicochemical properties of meloxicam, a new NSIAD. Eur. J. Pharm. Sci. 4 (1996) 175-187
24. Martens M. Efficacy and tolerability of a topical NSAID patch (local action transcutaneous flurbiprofen) and oral dichlofenac in the treatment of soft-tissue rheumatism. Clin. Rheumtol. 16 (1997) 25-31
25. Matsuura M., Imayoshi T., and Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int. J. Immunopharmacol. 22 (2000) 323-331
26. Mazzenga G.C., and Berner B. The transdermal delivery of zwitterionic drugs I: the solubility of zwitterion salts. J. Control. Release 16 (1991) 77-88
27. Mazzenga G.C., Berner B., and Jordan F. The transdermal delivery of zwitterionic drugs I: the flux of zwitterion salts. J. Control. Release 20 (1992) 163-170
28. Megwa S.A., Cross S.E., Whitehouse M.W., Benson H.A., and Roberts M.S. Effect of ion pairing with alkylamines on the in-vitro dermal penetration and local tissue disposition of salicylates. J. Pharm. Pharmacol. 52 (2000) 929-940
29. Naidu N.B., Chowdary K.P.R., Murthy K.V.R., Satyanarayana V., Hayman A.R., and Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. 35 (2004) 75-86
30. O'Neil M.J., Heckelman P.E., Koch C.B., Roman K.J., Kenny C.M., and D'Arecca M.R. The Merck Index. 14th ed. (2006), Merck & Co., INC, NJ, USA
31. Pairet M., van Ryn J., Schierok H., Mauz A., Trummlitz G., and Engelhardt G. Differential inhibition of cyclooxygenasse-1 and -2 by meloxicam and its 4′-isomer. Inflamm. Res. 47 (1998) 270-276
32. Prieto A., De Barrio M., Martin E., Fernandez-Bohorqez M., De Castro F.J., Ruiz F.J., Herrero T., Tornero P., and Rubio M. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. J. Allergy Clin. Immunol. 119 (2007) 960-964
33. Satas D. Handbook of Pressure Sensitive Adhesive Technology. 2nd ed. (1989), Van Nostrand Reinhold, New York p. 109
34. Satas D. Handbook of Pressure Sensitive Adhesive Technology. 2nd ed. (1989), Van Nostrand Reinhold, New York p. 403
35. Senna G.E., Passalacqua G., Dama A., Crivellaro M., Schiappoli M., Bonadonna P., and Canonica G.W. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur. Ann. Allergy Clin. Immunol. 35 (2003) 393-396
36. Seti P., Kruss B., Wiegleb J., and Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parental, dermal and mucosal administration. Br. J. Rheumatol. 35 (1996) 44-50
37. Swingle K.F., Grant T.J., Jaques L.W., and Kvam D.C. Interactions of anti-inflammatory drugs in carrageenan-induced foot edema of the rat. J. Pharmcol. Exp. Ther. 172 (1969) 423-425
38. Tsai R.S., Carrupt P.A., Tayar N.E., Giroud Y., Andrade P., and Testa B. Physicochemical and structural properties of non-steroidal anti-inflammatory oxicams. Helv. Chim. Acta. 76 (1993) 842-854
39. Wang R.J., Wu P.C., Huang Y.B., and Tsai Y.H. The effects of iontophoresis and electrophoration on transdermal delivery of meloxicam salts evaluated in-vitro and in-vivo. J. Food Drug Anal. 16 (2008) 41-48
40. Yuan Y., Li S.M., Mo F.K., and Zhong D.F. Investigation of microemulsion system for transdermal delivery of meloxicam. Int. J. Pharm. 321 (2006) 117-123
41. Yuan Y., Chen X., and Zhong D. Determination of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry following transdermal administration. J. Chromatogr. B 852 (2007) 650-654